Reference
The NIOSH List of Hazardous Drugs, 2024
All 236 drugs across Tables 1 and 2, and a separate EQUASHIELD vetted list of drugs NIOSH does not list. Brand names resolve to their generic.
236 of 236 drugs
| Drug | Table | Classification |
|---|---|---|
| ado-trastuzumab emtansinebiologic | Table 1 | 10:00 antineoplastic agents |
| altretamine | Table 1 | 10:00 antineoplastic agents |
| amsacrine | Table 1 | 10:00 antineoplastic agents · IARC Group 2B* |
| arsenic trioxide | Table 1 | 10:00 antineoplastic agents · IARC Group 1 carcinogen; NTP “known to be a human carcinogen” |
| azacitidine | Table 1 | 10:00 antineoplastic agents · IARC Group 2A carcinogen; NTP “reasonably anticipated to be a human carcinogen” |
| azathioprine | Table 1 | 92:44 immunosuppressive agents; 92:20 immunomodulatory agents; 92:36 disease-modifying antirheumatic drugs · IARC Group 1 carcinogen; NTP “known to be human carcinogen” |
| belantamab mafodotinbiologic | Table 1 | 10:00 antineoplastic agents |
| belinostat | Table 1 | 10:00 antineoplastic agents |
| bendamustine | Table 1 | 10:00 antineoplastic agents |
| bleomycin | Table 1 | 10:00 antineoplastic agents · IARC Group 2B* |
| bortezomib | Table 1 | 10:00 antineoplastic agents |
| brentuximab vedotinbiologic | Table 1 | 10:00 antineoplastic agents |
| busulfan | Table 1 | 10:00 antineoplastic agents · IARC Group 1 carcinogen |
| cabazitaxel | Table 1 | 10:00 antineoplastic agents |
| capecitabine | Table 1 | 10:00 antineoplastic agents |
| carboplatin | Table 1 | 10:00 antineoplastic agents |
| carmustine | Table 1 | 10:00 antineoplastic agents · IARC Group 2A carcinogen |
| chlorambucil | Table 1 | 10:00 antineoplastic agents · IARC Group 1 carcinogen; NTP “known to be human carcinogen” |
| chloramphenicol | Table 1 | 8:12.08 chloramphenicol · IARC Group 2A carcinogen; NTP “reasonably anticipated to be a human carcinogen” |
| cidofovir | Table 1 | 8:18.32 nucleosides and nucleotides |
| cisplatin | Table 1 | 10:00 antineoplastic agents · IARC Group 2A carcinogen; NTP “reasonably anticipated to be a human carcinogen” |
| cladribine | Table 1 | 10:00 antineoplastic agents |
| clofarabine | Table 1 | 10:00 antineoplastic agents |
| cyclophosphamide | Table 1 | 10:00 antineoplastic agents; 92:44 immunosuppressive agents · IARC Group 1 carcinogen; NTP “known to be human carcinogen” |
| cyclosporine | Table 1 | 52:08.92 anti-inflammatory agents; 92:44 immunosuppressive agents; 92:20 immunomodulatory agents; 92:36 disease- modifying antirheumatic drugs · IARC Group 1 carcinogen; NTP “known to be human carcinogen” |
| cytarabine | Table 1 | 10:00 antineoplastic agents |
| dacarbazine | Table 1 | 10:00 antineoplastic agents · IARC Group 2B; NTP “reasonably anticipated to be a human carcinogen” * |
| dactinomycin | Table 1 | 10:00 antineoplastic agents |
| dasatinib | Table 1 | 10:00 antineoplastic agents |
| daunorubicin | Table 1 | 10:00 antineoplastic agents · IARC Group 2B* |
| decitabine | Table 1 | 10:00 antineoplastic agents |
| dexrazoxane | Table 1 | 92:56 protective agents |
| diethylstilbestrol | Table 1 | — · IARC Group 1 carcinogen; NTP “known to be a human carcinogen” |
| docetaxel | Table 1 | 10:00 antineoplastic agents |
| doxorubicin | Table 1 | 10:00 antineoplastic agents · IARC Group 2A carcinogen; NTP “reasonably anticipated to be a human carcinogen”* |
| enfortumab vedotinbiologic | Table 1 | 10:00 antineoplastic agents |
| epirubicin | Table 1 | 10:00 antineoplastic agents |
| eribulin mesylate | Table 1 | 10:00 antineoplastic agents |
| estramustine | Table 1 | 10:00 antineoplastic agents |
| estrogen/ progesterone combinations | Table 1 | 68:12 contraceptives; 68:16.04 estrogens; 68:32 progestins · IARC Group 1 carcinogen; NTP “known to be a human carcinogen” |
| estrogens, conjugated | Table 1 | 68:16.04 estrogens; 92:24 bone resorption inhibitors · NTP “known to be a human carcinogen” |
| estrogens, esterified | Table 1 | 68:16.04 estrogens; 92:24 bone resorption Inhibitors · NTP “known to be a human carcinogen” |
| etoposide | Table 1 | 10:00 antineoplastic agents · IARC Group 1 carcinogen |
| everolimus | Table 1 | 10:00 antineoplastic agents; 92:44 immunosuppressive agents |
| fam-trastuzumab deruxtecanbiologic | Table 1 | 10:00 antineoplastic agents |
| floxuridine | Table 1 | 10:00 antineoplastic agents |
| fludarabine | Table 1 | 10:00 antineoplastic agents |
| fluorouracil | Table 1 | 10:00 antineoplastic agents; 84:92 skin and mucous membrane agents, miscellaneous |
| ganciclovir | Table 1 | 8:18.32 nucleosides and nucleotides; 52:04.20 antivirals |
| gemcitabine | Table 1 | 10:00 antineoplastic agents |
| gemtuzumab ozogamicinbiologic | Table 1 | 10:00 antineoplastic agents |
| hydroxyurea | Table 1 | 10:00 antineoplastic agents |
| idarubicin | Table 1 | 10:00 antineoplastic agents |
| ifosfamide | Table 1 | 10:00 antineoplastic agents |
| imatinib | Table 1 | 10:00 antineoplastic agents |
| inotuzumab ozogamicinbiologic | Table 1 | 10:00 antineoplastic agents |
| irinotecan | Table 1 | 10:00 antineoplastic agents |
| ixabepilone | Table 1 | 10:00 antineoplastic agents |
| ixazomib | Table 1 | 10:00 antineoplastic agents |
| lenalidomide | Table 1 | 10:00 antineoplastic agents; 92:20 immunomodulatory agents |
| loncastuximab tesirinebiologic | Table 1 | 10:00 antineoplastic agents |
| lomustine | Table 1 | 10:00 antineoplastic agents · IARC Group 2A carcinogen |
| lurbinectedin | Table 1 | 10:00 antineoplastic agents |
| mechlorethamine | Table 1 | 10:00 antineoplastic agents; 84:92 skin and mucous membrane agents, miscellaneous |
| melphalan | Table 1 | 10:00 antineoplastic agents · IARC Group 1 carcinogen; NTP “known to be a human carcinogen” |
| melphalan flufenamide | Table 1 | 10:00 antineoplastic agents |
| mercaptopurine | Table 1 | 10:00 antineoplastic agents; 92:44 immunosuppressive agents |
| methotrexate | Table 1 | 10:00 antineoplastic agents; 92:20 immunomodulatory agents; 92:36 disease-modifying antirheumatic drugs; 92:44 immunosuppressive agents |
| mirvetuximab soravtansinebiologic | Table 1 | 10:00 antineoplastic agents |
| mitomycin | Table 1 | 10:00 antineoplastic agents · IARC Group 2B* |
| mitotane | Table 1 | 10:00 antineoplastic agents |
| mitoxantrone | Table 1 | 10:00 antineoplastic agents · IARC Group 2B* |
| mycophenolate mofetil | Table 1 | 92:44 immunosuppressive agents |
| nelarabine | Table 1 | 10:00 antineoplastic agents |
| omacetaxine | Table 1 | 10:00 antineoplastic agents |
| oxaliplatin | Table 1 | 10:00 antineoplastic agents |
| paclitaxel | Table 1 | 10:00 antineoplastic agents |
| panobinostat | Table 1 | 10:00 antineoplastic agents |
| pemetrexed | Table 1 | 10:00 antineoplastic agents |
| pentostatin | Table 1 | 10:00 antineoplastic agents |
| polatuzumab vedotinbiologic | Table 1 | 10:00 antineoplastic agents |
| pomalidomide | Table 1 | 10:00 antineoplastic agents; 92:20 immunomodulatory agents |
| pralatrexate | Table 1 | 10:00 antineoplastic agents |
| procarbazine | Table 1 | 10:00 antineoplastic agents · IARC Group 2A carcinogen |
| romidepsin | Table 1 | 10:00 antineoplastic agents |
| sacituzumab govitecanbiologic | Table 1 | 10:00 antineoplastic agents |
| streptozocin | Table 1 | 10:00 antineoplastic agents · IARC Group 2B; NTP “reasonably anticipated to be a human carcinogen” * |
| tamoxifen | Table 1 | 10:00 antineoplastic agents; 68:16.12 estrogen agonists- antagonists · IARC Group 1 carcinogen; NTP “known to be a human carcinogen” |
| temozolomide | Table 1 | 10:00 antineoplastic agents |
| temsirolimus | Table 1 | 10:00 antineoplastic agents |
| teniposide | Table 1 | 10:00 antineoplastic agents · IARC Group 2A carcinogen |
| thalidomide | Table 1 | 92:20 immunomodulatory agents |
| thioguanine | Table 1 | 10:00 antineoplastic agents |
| thiotepa | Table 1 | 10:00 antineoplastic agents · IARC Group 1 carcinogen; NTP “known to be a human carcinogen” |
| tisotumab-vedotinbiologic | Table 1 | 10:00 antineoplastic agents |
| topotecan | Table 1 | 10:00 antineoplastic agents |
| trabectedin | Table 1 | 10:00 antineoplastic agents |
| trifluridine | Table 1 | 10:00 antineoplastic agents |
| uracil mustard | Table 1 | — · IARC Group 2B* |
| valganciclovir | Table 1 | 8:18.32 nucleosides and nucleotides |
| valrubicin | Table 1 | 10:00 antineoplastic agents |
| vandetanib | Table 1 | 10:00 antineoplastic agents |
| vinblastine | Table 1 | 10:00 antineoplastic agents |
| vincristine | Table 1 | 10:00 antineoplastic agents |
| vinorelbine | Table 1 | 10:00 antineoplastic agents |
| vorinostat | Table 1 | 10:00 antineoplastic agents |
| abacavir | Table 2 | 8:18.08.20 HIV nucleoside and nucleotide reverse transcriptase inhibitors |
| abiraterone | Table 2 | 10:00 antineoplastic agents |
| acitretin | Table 2 | 84:92 skin and mucous membrane agents, miscellaneous |
| afatinib | Table 2 | 10:00 antineoplastic agents |
| alefaceptbiologic | Table 2 | 84:92 skin and mucous membrane agents, miscellaneous; 92:44 immunosuppressive agents |
| alitretinoin | Table 2 | 84:92 skin and mucous membrane agents, miscellaneous |
| ambrisentan | Table 2 | 48:48 vasodilating agents; 24:12.92 vasodilating agents, miscellaneous |
| anastrozole | Table 2 | 68:16.08 antiestrogens; 10:00 antineoplastic agents |
| apomorphine | Table 2 | 28:36.20.08 nonergot- derivative dopamine receptor agonists |
| axitinib | Table 2 | 10:00 antineoplastic agents |
| bexarotene | Table 2 | 10:00 antineoplastic agents; 84:92 skin and mucous membrane agents, miscellaneous |
| bicalutamide | Table 2 | 10:00 antineoplastic agents |
| blinatumomabbiologic | Table 2 | 10:00 antineoplastic agents |
| bosentan | Table 2 | 48:48 vasodilating agents; 24:12.92 vasodilating agents, miscellaneous |
| bosutinib | Table 2 | 10:00 antineoplastic agents |
| cabergoline | Table 2 | 28:36.20.04 ergot-derivative dopamine receptor agonists |
| cabozantinib | Table 2 | 10:00 antineoplastic agents |
| carbamazepine | Table 2 | 28:12.92 anticonvulsants, miscellaneous; 28:28 antimanic agents |
| carfilzomib | Table 2 | 10:00 antineoplastic agents |
| ceritinib | Table 2 | 10:00 antineoplastic agents |
| cetrorelix | Table 2 | 68:18.04 antigonadotropins |
| choriogonadotropinbiologic | Table 2 | 68:18.08 gonadotropins |
| clobazam | Table 2 | 28:12.08 benzodiazepines; 28:24.08 benzodiazepines |
| clomiphene | Table 2 | 68:16.12 estrogen agonist- antagonists |
| clonazepam | Table 2 | 28:12.08 benzodiazepines; 28:24.08 benzodiazepines |
| cobimetinib | Table 2 | 10:00 antineoplastic agents |
| colchicine | Table 2 | 92:16 antigout agents |
| crizotinib | Table 2 | 10:00 antineoplastic agents |
| dabrafenib | Table 2 | 10:00 antineoplastic agents |
| deferiprone | Table 2 | 64:00 heavy metal antagonists |
| degarelix | Table 2 | 68:18.04 antigonadotropins; 10:00 antineoplastic agents |
| dihydroergotamine | Table 2 | 12:16.04.04 non-selective alpha-adrenergic blocking agents; 28:32.92 antimigraine agents, miscellaneous |
| dinoprostone | Table 2 | 76:00 oxytocics |
| divalproex | Table 2 | 28:12.92 anticonvulsants, miscellaneous; 28:28 antimanic |
| dronedarone | Table 2 | 24:04.04.20 Class III antiarrhythmics |
| dutasteride | Table 2 | 92:08 5-alpha reductase inhibitors |
| entecavir | Table 2 | 8:18.32 nucleosides and nucleotides |
| enzalutamide | Table 2 | 10:00 antineoplastic agents |
| erlotinib | Table 2 | 10:00 antineoplastic agents |
| eslicarbazepine | Table 2 | 28:12.92 anticonvulsants, miscellaneous |
| estradiol | Table 2 | 68:16.04 estrogens; 92:24 bone resorption inhibitors |
| estropipate | Table 2 | 68:16.04 estrogens |
| exemestane | Table 2 | 68.16.08 antiestrogens; 10:00 antineoplastic agents |
| exenatide | Table 2 | 68:20.06 incretin mimetics |
| finasteride | Table 2 | 84:92 skin and mucous membrane agents, miscellaneous; 92:08 5-alpha- reductase inhibitors |
| fingolimod | Table 2 | 92:20 immunomodulatory agents |
| fluconazole | Table 2 | 8:14.08 azoles |
| fluoxymesterone | Table 2 | 68:08 androgens |
| flutamide | Table 2 | 10:00 antineoplastic agents |
| fosphenytoin | Table 2 | 28:12.12 hydantoins |
| fulvestrant | Table 2 | 10:00 antineoplastic agents |
| ganirelix | Table 2 | 68:18.04 antigonadotropins |
| gonadotropin, chorionicbiologic | Table 2 | 68:18.08 gonadotropins |
| goserelin | Table 2 | 68:18.08 gonadotropins; 10:00 antineoplastic agents |
| histrelin | Table 2 | 68:18.08 gonadotropins; 10:00 antineoplastic agents |
| icatibant | Table 2 | 92:32 complement inhibitors |
| isotretinoin | Table 2 | 84:92 skin and mucous membrane agents, miscellaneous |
| ivabradine | Table 2 | 24:04.92 cardiac drugs, miscellaneous |
| leflunomide | Table 2 | 92:36 disease-modifying antirheumatic agents; 92:20 immunomodulatory agents |
| lenvatinib | Table 2 | 10:00 antineoplastic agents |
| letrozole | Table 2 | 68.16.08 antiestrogens: 10:00 antineoplastic agents |
| leuprolide | Table 2 | 68:18.08 gonadotropins; 10:00 antineoplastic agents |
| lomitapide | Table 2 | 24:06.92 antilipemic agents, miscellaneous |
| macitentan | Table 2 | 48:48 vasodilating agents; 24:12.92 vasodilating agents, miscellaneous |
| medroxyprogesterone | Table 2 | 68:32 progestins; 68:12 contraceptives |
| megestrol | Table 2 | 68:32 progestins; 10:00 antineoplastic agents |
| menotropinsbiologic | Table 2 | NA gonadotropins |
| methimazole | Table 2 | 68:36.08 antithyroid agents |
| methylergonovine | Table 2 | 76:00 oxytocics |
| methyltestosterone | Table 2 | 68:08 androgens |
| mifepristone | Table 2 | 76:00 oxytocics |
| miltefosine | Table 2 | 8:30.92 miscellaneous antiprotozoals |
| mipomersen | Table 2 | 24:06.92 antilipemic agents, miscellaneous; 92:18 antisense oligonucleotides |
| misoprostol | Table 2 | 56:28.28 prostaglandins |
| mycophenolic acid | Table 2 | 92:44 immunosuppressive agents |
| nafarelin | Table 2 | 68:18.08 gonadotropins |
| nevirapine | Table 2 | 8:18.08.16 HIV nonnucleoside reverse transcriptase inhibitors |
| nilotinib | Table 2 | 10:00 antineoplastic agents |
| olaparib | Table 2 | 10:00 antineoplastic agents |
| ospemifene | Table 2 | 68:16.12 estrogen agonist- antagonists |
| oxcarbazepine | Table 2 | 28:12.92 anticonvulsants, miscellaneous |
| oxytocin | Table 2 | 76:00 oxytocics |
| paliferminbiologic | Table 2 | 84:16 cell stimulants and proliferants |
| pamidronate | Table 2 | 92:24 bone resorption inhibitors |
| paroxetine | Table 2 | 28:16.04.20 selective serotonin uptake inhibitors |
| pasireotide | Table 2 | 68:29.04 somatostatin agonists |
| pazopanib | Table 2 | 10:00 antineoplastic agents |
| peginesatide | Table 2 | 20:16 hematopoietic |
| pentetate calcium trisodium | Table 2 | — |
| phenoxybenzamine | Table 2 | 12:16.04.04 non-selective alpha-adrenergic blocking agents; 24:08.92 hypotensive agents, miscellaneous |
| phenytoin | Table 2 | 28:12.12 hydantoins; 24:04.04.08 Class Ib antiarrhythmics |
| pipobroman | Table 2 | — |
| plerixafor | Table 2 | 20:16 hematopoietic agents |
| ponatinib | Table 2 | 10:00 antineoplastic agents |
| progesterone | Table 2 | 68:32 progestins |
| progestins | Table 2 | 68:12 contraceptives; 68:32 progestins |
| propylthiouracil | Table 2 | 68:36.08 antithyroid agents |
| raloxifene | Table 2 | 68:16.12 estrogen agonists- antagonists; 10:00 antineoplastic agents; 92:24 bone resorption inhibitors |
| rasagiline | Table 2 | 28:36 antiparkinsonian agents; 28:16.04.12 monoamine oxidase inhibitors |
| regorafenib | Table 2 | 10:00 antineoplastic agents |
| ribavirin | Table 2 | 8:18.32 nucleosides and nucleotides |
| riociguat | Table 2 | 48:48 vasodilating agents; 24:12.92 vasodilating agents, miscellaneous |
| sirolimus | Table 2 | 92:44 immunosuppressive agents |
| sonidegib | Table 2 | 10:00 antineoplastic agents |
| sorafenib | Table 2 | 10:00 antineoplastic agents |
| spironolactone | Table 2 | 24:32.20 mineralocorticoid (aldosterone) receptor antagonists; 24:08.24.16 potassium-sparing diuretics; 24:08.44.20 mineralocorticoid (aldosterone) receptor antagonists; 40:28.16 potassium-sparing diuretics |
| sunitinib | Table 2 | 10:00 antineoplastic agents |
| tacrolimus | Table 2 | 84:92 skin and mucous membrane agents, miscellaneous; 92:44 immunosuppressive agents |
| temazepam | Table 2 | 28:24.08 benzodiazepines |
| teriflunomide | Table 2 | 92:20 immunomodulatory agents |
| testosterone | Table 2 | 68:08 androgens |
| tofacitinib | Table 2 | 92:36 disease-modifying antirheumatic drugs; 92:20 immunomodulatory agents |
| topiramate | Table 2 | 28:12.92 anticonvulsants, miscellaneous; 28:32.92 antimigraine agents, miscellaneous |
| toremifene | Table 2 | 68.16.12 estrogen agonist- antagonists; 10:00 antineoplastic agents |
| trametinib | Table 2 | 10:00 antineoplastic agents |
| tretinoin | Table 2 | 84:16 cell stimulants and proliferants |
| triptorelin | Table 2 | 68:18.08 gonadotropins; 10:00 antineoplastic agents |
| ulipristal | Table 2 | 68:12 contraceptives |
| urofollitropinbiologic | Table 2 | NA gonadotropins |
| valproate/valproic acid | Table 2 | 28:12.92 anticonvulsants, miscellaneous; 28:28 antimanic agents; 28:32.92 antimigraine agents, miscellaneous |
| vemurafenib | Table 2 | 10:00 antineoplastic agents |
| vigabatrin | Table 2 | 28:12.92 anticonvulsants, miscellaneous |
| vismodegib | Table 2 | 10:00 antineoplastic agents |
| voriconazole | Table 2 | 8:14.08 azoles |
| warfarin | Table 2 | 20:12.04.08 coumarin derivatives |
| zidovudine | Table 2 | 8:18.08.20 HIV nucleoside and nucleotide reverse transcriptase inhibitors |
| ziprasidone | Table 2 | 28:16.08.04 atypical antipsychotics; 28:28 antimanic agents |
| ziv-afliberceptbiologic | Table 2 | 10:00 antineoplastic agents |
| zoledronic acid | Table 2 | 92:24 bone resorption inhibitors |
| zonisamide | Table 2 | 28:12.92 anticonvulsants, miscellaneous |